Historique
Article de Périodique
Determinants of interest in extended-released buprenorphine: A survey among 366 French patients treated with buprenorphine or methadone (2021)
Auteur(s) :
ROLLAND, B. ;
TROJAK, B. ;
NOURREDINE, M. ;
BACHELLIER, J. ;
CHAPPUY, M. ;
BENDIMERAD, P. ;
KOSIM, M. ;
HJELMSTROM, P. ;
MEROUEH, F. ;
NUBUKPO, P. ;
BROUSSE, G.
Année
2021
Page(s) :
art. 108492
Langue(s) :
Anglais
Domaine :
Autres substances / Other substances
Thésaurus géographique
FRANCE
Thésaurus mots-clés
BUPRENORPHINE
;
ETUDE CLINIQUE
;
PREFERENCE
;
METHADONE
;
TRAITEMENT DE MAINTENANCE
;
PROFIL SOCIO-DEMOGRAPHIQUE
Résumé :
Aim: To explore the factors determining the interest in extended-release buprenorphine (XR-BUP) injections among patients receiving opioid agonist treatment (OAT) in France.
Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment.
Results: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring >=7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95% = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95% = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95%CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95%CI = 1.67-7.69) and craving (aOR = 2.38; 95%CI = 1.39-4.02) or improving family (aOR = 1.81; 95%CI = 1.03-3.13) or professional (aOR = 2.22; 95%CI = 1.43-3.85) recovery.
Conclusions: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
Highlights:
• The level of interest in XR-BUP among patients on OAT was high (median score = 7/10).
• The "more interested" participants (=score >=7/10) did not differ on sociodemographics.
• They did not differ either on clinical features (e.g., duration / type of OAT).
• They differed on treatment objectives (more focused on abstinence and recovery).
• They more frequently considered daily intake of oral OAT as a constraint.
Methods: 366 patients receiving OAT for opioid use disorder, recruited in 66 French centers, were interviewed from 12/2018 to 05/2019. A structured questionnaire assessed their interest in XR-BUP using a [1-10] Likert scale. 'More' vs. 'less' interested groups were defined using the median score of interest, and their characteristics were explored using adjusted odds ratios (aORs) and 95 % confidence interval (95 %CI). Independent variables were as follows: sociodemographic characteristics, OAT-related features (e.g., type of OAT and prescriber, dosing, or duration of treatment), OAT representations, and personal objectives of treatment.
Results: The median interest in XR-BUP was 7 (interquartile range: 3-9) out of 10. The participants who were 'more interested' (i.e. those scoring >=7) showed no substantial difference in sociodemographic characteristics, relative to the 'less interested' participants. However, they more frequently reported forgetting to take their OAT (OR = 1.81; CI95% = 1.06-3.10) or reported experiencing situations where taking their OAT was impractical (aOR = 1.69; CI95% = 1.05-2.73). Their treatment objective was more focused on stopping illicit drugs (aOR = 1.67; 95%CI = 1.02-2.70), reducing health risks (aOR = 3.57; 95%CI = 1.67-7.69) and craving (aOR = 2.38; 95%CI = 1.39-4.02) or improving family (aOR = 1.81; 95%CI = 1.03-3.13) or professional (aOR = 2.22; 95%CI = 1.43-3.85) recovery.
Conclusions: In France, where the access to OAT is relatively unrestricted, the majority of participants were interested in XR-BUP formulations. Being interested was associated with treatment objectives focused on abstinence and recovery, and with experiencing constraints in taking a daily oral OAT.
Highlights:
• The level of interest in XR-BUP among patients on OAT was high (median score = 7/10).
• The "more interested" participants (=score >=7/10) did not differ on sociodemographics.
• They did not differ either on clinical features (e.g., duration / type of OAT).
• They differed on treatment objectives (more focused on abstinence and recovery).
• They more frequently considered daily intake of oral OAT as a constraint.
Affiliation :
Service Universitaire d’Addictologie de Lyon (SUAL), CH Le Vinatier, Bron, France